<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01740479</url>
  </required_header>
  <id_info>
    <org_study_id>COMPLETE-2012</org_study_id>
    <nct_id>NCT01740479</nct_id>
  </id_info>
  <brief_title>Complete vs Culprit-only Revascularization to Treat Multi-vessel Disease After Early PCI for STEMI</brief_title>
  <acronym>COMPLETE</acronym>
  <official_title>Randomized Comparative Effectiveness Study of Complete vs Culprit-only Revascularization Strategies to Treat Multi-vessel Disease After Early Percutaneous Coronary Intervention (PCI) for ST-segment Elevation Myocardial (STEMI) Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Population Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Population Health Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine whether, on a background of optimal medical therapy, including ticagrelor,&#xD;
      opening of all suitable narrowings or blockages found at the time of primary PCI for an acute&#xD;
      heart attack is better than treating only the culprit lesion in patients with multi-vessel&#xD;
      disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To determine if a strategy of multivessel revascularization involving PCI of all suitable&#xD;
      non-infarct related artery lesions plus optimal medical therapy is superior to a strategy of&#xD;
      optimal medical therapy alone in reducing (1) the composite outcome of cardiovascular (CV)&#xD;
      death or new myocardial infarction (MI), or (2) the composite of CV death, new MI or ischemia&#xD;
      driven revascularization (IDR) in patients with multivessel disease who have undergone early&#xD;
      successful culprit lesion PCI for STEMI.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 1, 2013</start_date>
  <completion_date type="Actual">June 7, 2019</completion_date>
  <primary_completion_date type="Actual">June 7, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite of Cardiovascular death or new myocardial Infarction</measure>
    <time_frame>over duration of follow-up (average of approximately 4 years)</time_frame>
    <description>Co-primary outcome: CV death or new MI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Composite of cardiovascular death, new myocardial infarction or ischemia-driven revascularization</measure>
    <time_frame>over duration of follow-up (average of approximately 4 years)</time_frame>
    <description>Co-primary outcome: CV death, new MI or IDR</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite of CV death, new MI, ischemia-driven revascularization or hospitalization for unstable angina or heart failure</measure>
    <time_frame>Over duration of follow-up (average of approximately 4 years)</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Major Bleeding</measure>
    <time_frame>Over duration of follow-up (average of approximately 4 years)</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">4042</enrollment>
  <condition>Acute Myocardial Infarction</condition>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Complete Revascularization Strategy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Complete Revascularization Strategy (Staged Non-Culprit Lesion PCI plus Optimal Medical Therapy): Staged PCI using second generation drug eluting stents (Promus Element Plus drug-eluting stent or newer version in this series is strongly recommended) of all suitable non-culprit lesions.&#xD;
All patients, regardless of randomized treatment allocation will receive optimal medical therapy consisting of risk factor modification and use of evidence-based therapies (including low dose acetylsalicylic acid (ASA) and ticagrelor).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Optimal Medical Therapy Alone</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Culprit lesion only Revascularization Strategy (Optimal Medical Therapy Alone): No further revascularization of non-culprit lesions.&#xD;
All patients, regardless of randomized treatment allocation will receive optimal medical therapy consisting of risk factor modification and use of evidence-based therapies (including low dose ASA and ticagrelor).</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Complete Revascularization Strategy</intervention_name>
    <description>Staged PCI using second generation drug eluting stents (Promus Element Plus drug-eluting stent or newer version in this series is strongly recommended) of all suitable non-culprit lesions plus optimal medical therapy.</description>
    <arm_group_label>Complete Revascularization Strategy</arm_group_label>
    <other_name>Staged Non-Culprit Lesion PCI plus Optimal Medical Therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Men and women within 72 hours after successful PCI (preferably using a drug eluting&#xD;
             stent) to the culprit lesion for STEMI. PCI for STEMI can be either primary PCI or&#xD;
             rescue PCI for failed fibrinolysis or a combination strategy where PCI is performed&#xD;
             routinely 3-12 hours after fibrinolysis AND&#xD;
&#xD;
          2. Multi-vessel disease defined as at least 1 additional non-infarct related coronary&#xD;
             artery lesion that is at least 2.5 mm in diameter that has not been stented as part of&#xD;
             the primary PCI and that is amenable to successful treatment with PCI and has:&#xD;
&#xD;
               -  At least 70% diameter stenosis (visual estimation) or&#xD;
&#xD;
               -  At least 50% diameter stenosis (visual estimation) with fractional flow reserve&#xD;
                  (FFR) â‰¤ 0.80&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Planned revascularization of non-culprit lesion&#xD;
&#xD;
          2. Planned surgical revascularization&#xD;
&#xD;
          3. Non-cardiovascular co-morbidity reducing life expectancy to &lt; 5 years&#xD;
&#xD;
          4. Any factor precluding 5 year follow-up&#xD;
&#xD;
          5. Prior Coronary Artery Bypass Graft (CABG) Surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shamir R Mehta, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>McMaster University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hamilton General Hospital</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>November 27, 2012</study_first_submitted>
  <study_first_submitted_qc>December 3, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2012</study_first_posted>
  <last_update_submitted>February 5, 2021</last_update_submitted>
  <last_update_submitted_qc>February 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>STEMI</keyword>
  <keyword>ticagrelor</keyword>
  <keyword>multi-vessel disease</keyword>
  <keyword>culprit lesion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

